- Home
- RVYL vs TPST Comparison
RVYL vs TPST Comparison
Compare RVYL & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVYL | TPST |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 11.1M |
| IPO Year | 2008 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RVYL | TPST |
|---|---|---|
| Price | $5.71 | $2.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 10.1K | ★ 56.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.34 | 21.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $55,998,000.00 | $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $297.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.14 | $0.60 |
| 52 Week High | $8.55 | $12.22 |
Technical Indicators
Market Signals| Indicator | RVYL | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 35.96 |
| Support Level | $5.34 | $2.14 |
| Resistance Level | $6.10 | $2.52 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 43.88 | 14.12 |
Price Performance
Historical ComparisonAbout RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.